<br>        Inclusion Criteria:<br><br>          -  Patients with established diagnosis of low to moderate adult rheumatoid arthritis,<br>             currently on Disease Modifying AntiRheumatic Drugs (DMARDs) therapy for at least six<br>             months and not longer than 10 years<br><br>        Exclusion Criteria:<br><br>          -  All the concomitant diseases or pathological conditions that could interfere and<br>             impact the assessment of the study treatment, or with the safety of the patient<br><br>          -  Previous clinical trials and previous biological therapy that could interfere with the<br>             results in the present clinical trial<br><br>          -  Patients must not have received any previous biological therapy for rheumatoid<br>             arthritis (RA)<br>      ;<br>        Inclusion Criteria:<br><br>          -  Patients with established diagnosis of low to moderate adult rheumatoid arthritis,<br>             currently on Disease Modifying AntiRheumatic Drugs (DMARDs) therapy for at least six<br>             months and not longer than 10 years<br><br>        Exclusion Criteria:<br><br>          -  All the concomitant diseases or pathological conditions that could interfere and<br>             impact the assessment of the study treatment, or with the safety of the patient<br><br>          -  Previous clinical trials and previous biological therapy that could interfere with the<br>             results in the present clinical trial<br><br>          -  Patients must not have received any previous biological therapy for rheumatoid<br>             arthritis (RA)<br>      ;<br>        Inclusion Criteria:<br><br>          -  Patients with established diagnosis of low to moderate adult rheumatoid arthritis,<br>             currently on Disease Modifying AntiRheumatic Drugs (DMARDs) therapy for at least six<br>             months and not longer than 10 years<br><br>        Exclusion Criteria:<br><br>          -  All the concomitant diseases or pathological conditions that could interfere and<br>             impact the assessment of the study treatment, or with the safety of the patient<br><br>          -  Previous clinical trials and previous biological therapy that could interfere with the<br>             results in the present clinical trial<br><br>          -  Patients must not have received any previous biological therapy for rheumatoid<br>             arthritis (RA)<br>      ;<br>        Inclusion Criteria:<br><br>          -  Patients with established diagnosis of low to moderate adult rheumatoid arthritis,<br>             currently on Disease Modifying AntiRheumatic Drugs (DMARDs) therapy for at least six<br>             months and not longer than 10 years<br><br>        Exclusion Criteria:<br><br>          -  All the concomitant diseases or pathological conditions that could interfere and<br>             impact the assessment of the study treatment, or with the safety of the patient<br><br>          -  Previous clinical trials and previous biological therapy that could interfere with the<br>             results in the present clinical trial<br><br>          -  Patients must not have received any previous biological therapy for rheumatoid<br>             arthritis (RA)<br>